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in the CEDIA buprenorphine assay should be the object of further 
studies. For MAR patients, more specific methods than CEDIA are 
recommended to omit negative sanctions based on false-positive or 
false-negative results.
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Introduction: Self-empowering patients on oral anticoagulation may 
improve their safety and the outcome of this therapy. The aim of 
this study was to evaluate the effect of an individual, video-assisted, 
1-hour education on patient knowledge and on anticoagulation sta-
bility as an intermediate end point.
Patients (or Materials) and Methods: In a cluster-randomized trial 
in 22 general practices, we investigated 369 patients who were on 
oral anticoagulation with phenprocoumon. In 11 practices, trained 
practice nurses educated the patients individually based on a 20-min-
ute video, a leaflet, and a concluding questionnaire. The education 
lasted three quarters of an hour to an hour. Patients in the 11 control 
practices were handed over the leaflet and otherwise treated as usual. 
Patient knowledge was evaluated by questionnaires before and 6 
months after the education; anticoagulation stability was evaluated 
by the international normalized ratio (INR) in the 6-month periods 
before and after the intervention.
Results: Six months after the intervention, the educated patients had 
better safety-relevant knowledge and their anticoagulation tended to 
be more stable than before the education. Knowledge and INR stabil-
ity did not change in the controls. In particular, 68% of the patients 
knew that acetaminophen (paracetamol) is the safest over-the-counter 
analgesic for the combination with phenprocoumon compared with 
22% before (P < 0.001). Basic diet rules were known to 71% of the 
patients compared with 30% before (P < 0.001). Painful swelling 
realized 60% as a signal symptom compared with 26% before (P < 
0.001). Suddenly disturbed speech was a signal symptom to 80% 
compared with 49% of these patients before the education (P < 
0.001). How to proceed after a forgotten intake knew 57% compared 
with 14% before the education (P < 0.001). The INR was outside 
the intended range for 29% of the time during the 6 months after 
the education in the intervention group compared with 36% of the 
time in the control patients (P = 0.09).
Conclusion: Self-empowering patients with this 1-hour education 
significantly improved patient knowledge over 6 months and tended 
to improve the intermediate end point INR stability. This education 
could be easily implemented in routine practice. In addition, this 
education provides a promising example to self-empower patients 
in further therapies.
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Introduction: Acenocoumarol is a vitamin K antagonist charac-
terized by a large interpatient variability in the dose required to 
achieve target anticoagulation. There is extensive evidence that a 
large part of the variability of VKAs can be explained by genetic 
factors, especially polymorphisms in the VKORC1 and the CYP2C9 
genes. The objective of this study was to investigate the impact of 
CYP2C9 polymorphisms and drug−drug interactions on the risk of 
overanticoagulation and on the mean daily dose in patients treated 
with acenocoumarol.
Patients (or Materials) and Methods: This prospective observational 
study included 115 hospitalized patients starting acenocoumarol treat-
ment. Data were collected during the first 35 days of therapy and included 
sex, age, INR measurements, acenocoumarol doses, comorbidities, and 
comedications. Patients were genotyped for CYP2C9, CYP2C19, and 
VKORC1. Drugs known to inhibit CYP2C9 using the table developed 
by the Division of Clinical Pharmacology and Toxicology, Geneva 
University Hospitals, Switzerland, were carefully listed.
Results: The difference for time to overanticoagulation in pres-
ence or absence of CYP2C9 inhibitors for all patients, independ-
ent of the genotype, was significant (P < 0.001). The presence of 
a CYP2C9 inhibitor or a CYP2C9 polymorphism, independently, 
statistically increased the risk of overanticoagulation (HR = 2.8 [P < 
0.001] and HR = 1.7 [P = 0.004], respectively). For CYP2C9*1/*1 
genotype only, in the presence of a CYP2C9 inhibitor, 52% of 
wild-type patients presented an INR ≥ 4 versus 22% in absence of 
a CYP2C9 inhibitor. In wild-type patients, the HR was 2.7 (P = 
0.02) in the presence of a CYP2C9 inhibitor compared with the 
absence of CYP2C9 inhibitor. For patients carriers of CYP2C9*2 or 
CYP2C9*3 alleles, in the presence of a CYP2C9 inhibitor, 78% of 
carriers presented an INR ≥ 4 versus 48% in the absence of CYP2C9 
inhibitor. For patients carriers of CYP2C9*2 or CYP2C9*3 alleles, 
the HR was 2.9 (P = 0.01) in presence of a CYP2C9 inhibitor. 
Presence of the CYP2C9*3 allele and VKORC1-1639GA and 
VKORC1-1639AA were significantly associated with a lower dose 
compared with wild-type subjects with a decrease of nearly 35%, 
25%, and 45%, respectively, in dose requirement. CYP2C9*2 and 
CYP2C19*2 were not associated with lower acenocoumarol doses. 
The presence of a CYP2C9 inhibitor was associated with a decrease 
of 20% in dose requirement (P < 0.05).
Conclusion: The results of our study confirm that the presence of at 
least 1 allelic variant of CYP2C9 and/or the prescription of CYP2C9 
inhibitors expose patients to an increased additive risk of overanti-
coagulation. The VKORC1-1639GA and -1639AA genotypes and 
the presence of a CYP2C9*3 allele were associated with a lower dose 
of acenocoumarol. These findings support that CYP2C9 genotyping 
could be useful for identifying patients requiring a closer monitoring, 
especially in the presence of a CYP2C9 inhibitor.
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